Mesothelioma Researchers Seek More Effectiveness from Immunotherapy
The objective-response rate was 9 percent, which included one patient with a complete response and disappearance of all tumor burden, and four patients with a partial response.
Of the 48 patients whose data were assessed for change in tumor size, 24 experienced a reduction of some level.
Most encouraging were the patients with a higher-level of PD-L1. They had a median overall survival of 20.2 months and a 12-month overall survival of 72.5 percent.
PD-L1 presence alone, though, is not considered the only factor in how well the drug would work. Other factors such as genetic mutations of the tumor and mesothelioma cell type ...
Source: Asbestos and Mesothelioma News - January 17, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news
Debate Continues on When Best to Use Mesothelioma Chemotherapy
This study is pretty reassuring that half the patients aren’t getting a more optimal or superior approach,” Simone said. “Both are good, accepted approaches. It’s more what the institution is comfortable with, and how the doctors are trained to do it.”
European Trial May Be More Definitive
The ongoing clinical trial is being done at centers in Belgium, France and the Netherlands. The European Organization for Research and Treatment of Cancer is sponsoring the study.
The goal is 64 patients, half of whom will undergo pleurectomy and decortication surgery followed by three cycles of pemetrexed and cisplatin chemoth...
Source: Asbestos and Mesothelioma News - January 3, 2019 Category: Environmental Health Authors: Matt Mauney Source Type: news
Alimta-Related Skin Reactions with and Without Oral Steroids
This study supports the use of intravenous dexamethasone 10 mg before pemetrexed infusion in place of three days of oral dexamethasone 4 mg twice daily at UNMCCC,” the authors wrote.
The post Alimta-Related Skin Reactions with and Without Oral Steroids appeared first on Mesothelioma Center - Vital Services for Cancer Patients & Families. (Source: Asbestos and Mesothelioma News)
Source: Asbestos and Mesothelioma News - November 5, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news
UK Study Matches Mesothelioma Treatments to Genetic Profile
University of Leicester researchers soon will open the first molecularly stratified clinical trial for malignant mesothelioma with the hope of moving the future of treatment toward more personalization.
The phase II trial in the United Kingdom is designed to match therapy with a patient’s specific genetic profile.
“We’re trying to bring the right drug to the right patient at the right time,” Professor Dean Fennell, chair of thoracic medical oncology at Leicester and chief trial investigator, told Asbestos.com. “We need to find different treatments that work for different people. This is a step in that direction....
Source: Asbestos and Mesothelioma News - October 12, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news
Review Highlights Better Targets for Mesothelioma Therapy
A review on targeted therapies for malignant pleural mesothelioma (MPM) provides fresh insight into why this cancer is so difficult to treat and ideas for improving outcomes.
“Despite more than two decades of intensive research on the possible treatments for MPM, the results have so far been disappointing,” the authors wrote.
According to the in-depth review, published in Critical Reviews in Hematology/Oncology, the next steps toward more tailored mesothelioma treatment will come from learning more about the changes driving abnormal cell communication.
Researchers will use this information to personalize treatments bas...
Source: Asbestos and Mesothelioma News - October 4, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news
Roche ’s Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in a type of previously untreated advanced lung cancer
Roche today announced results from the Phase III IMpower132 study of Tecentriq ® (atezolizumab) plus pemetrexed and platinum-based chemotherapy (cisplatin or carboplatin) for the initial (first-line) treatment of people with non-squamous, non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - September 24, 2018 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in a type of previously untreated advanced lung cancer
Roche today announced results from the Phase III IMpower132 study of Tecentriq ® (atezolizumab) plus pemetrexed and platinum-based chemotherapy (cisplatin or carboplatin) for the initial (first-line) treatment of people with non-squamous, non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - September 24, 2018 Category: Pharmaceuticals Source Type: news
Novel Mesothelioma Treatment Closer to FDA Approval
Standard-of-care treatment for patients with pleural mesothelioma may soon include Tumor Treating Fields (TTF), a novel therapy involving electric currents that disrupt cancer cell division and inhibit tumor growth.
In the wake of recently released results from Novocure’s STELLAR phase II clinical trial, the U.S. Food and Drug Administration (FDA) is expected to approve the treatment within the next six months, giving mesothelioma patients another much-needed option.
“At this point, it should be a relatively rapid approval process,” Dr. Eilon Kirson, chief science officer at Novocure, the oncology company designing t...
Source: Asbestos and Mesothelioma News - September 17, 2018 Category: Environmental Health Authors: Matt Mauney Source Type: news
EC Approves Frontline Lung Cancer Combo EC Approves Frontline Lung Cancer Combo
The European Commission (EC) has approved the combination of pembrolizumab, pemetrexed, and platinum chemotherapy for the first-line treatment of metastatic non – small cell lung cancer.International Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - September 13, 2018 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news
Novocure touts combined TTF, chemotherapy mesothelioma study data
Novocure (NSDQ:NVCR) today released results from the Stellar phase 2 registration trial exploring the use of its Tumor Treating Fields and standard of care chemotherapy to chemotherapy alone in treating mesothelioma, touting a significant extension in median overall survival.
Patients with malignant pleural mesothelioma who received TTF treatment alongside pemetrexed and cisplatin or carboplatin experienced a median overall survival of 18.2 months, compared to 12.1 months in a historical control, the St. Helier, Jersey-based company said.
Read the whole story on our sister site, Drug Delivery Business News
The post Novocu...
Source: Mass Device - September 6, 2018 Category: Medical Devices Authors: Fink Densford Tags: Clinical Trials Drug-Device Combinations Oncology NovoCure Source Type: news
Mesothelioma Case Report Touts Success with Opdivo
Not every mesothelioma patient benefits from the immunotherapy drug Opdivo, but for the ones that do, the response can be lifesaving.
Opdivo, known generically as nivolumab, continues to produce dramatic results, inching it closer to FDA approval for mesothelioma cancer.
A recently published individual case report describes “an exceptional and sustained response.” Treatment with Opdivo allowed one patient to go from a downward spiral, with only weeks to live, back into the workforce.
“We were blown away by the patient’s response,” lead author Riley Jones, now in his fellowship at the University of Florida College...
Source: Asbestos and Mesothelioma News - July 23, 2018 Category: Environmental Health Authors: Daniel King Source Type: news
Roche ’s Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in the initial treatment of people with advanced lung cancer
Roche today announced that the Phase III IMpower132 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of Tecentriq ® (atezolizumab) plus chemotherapy (cisplatin or carboplatin plus pemetrexed) reduced the risk of disease worsening or death (PFS) compared to chemotherapy alone in the initial (first-line) treatment of advanced non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Investor Update)
Source: Roche Investor Update - July 19, 2018 Category: Pharmaceuticals Source Type: news
Roche ’s Tecentriq in combination with pemetrexed and platinum-based chemotherapy reduced the risk of disease worsening or death in the initial treatment of people with advanced lung cancer
Roche today announced that the Phase III IMpower132 study met its co-primary endpoint of progression-free survival (PFS) and demonstrated that the combination of Tecentriq ® (atezolizumab) plus chemotherapy (cisplatin or carboplatin plus pemetrexed) reduced the risk of disease worsening or death (PFS) compared to chemotherapy alone in the initial (first-line) treatment of advanced non-squamous non-small cell lung cancer (NSCLC). (Source: Roche Media News)
Source: Roche Media News - July 19, 2018 Category: Pharmaceuticals Source Type: news
Dr Reddy's loses patent case with Eli Lilly over Alimta
The U.S. District Court for the Southern District of Indiana ruled in favor of Lilly, a release from the US drug maker said. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - June 24, 2018 Category: Pharmaceuticals Source Type: news
U.S. District Court rules in favor of Lilly's Alimta patent
(Reuters) - Eli Lilly and Co said on Friday a U.S. District Court ruled in favor of its patent on Alimta vitamin regimen and prevented Hospira Inc and India's Dr. Reddy's Laboratories from launching generics until the patent expires. (Source: Reuters: Health)
Source: Reuters: Health - June 22, 2018 Category: Consumer Health News Tags: healthNews Source Type: news
